EVOGENE LTD

Insightful analysis of Evogene’s insider buying shows management confidence in its AI‑driven drug‑discovery platform and a potential short‑term rally ahead of Q2 earnings.

EVOGENE insider RECANATI LEON buys 460,000 shares at $0.64, signaling confidence in the AI‑driven biotech’s future amid steep volatility.

Insider RECANATI LEON’s steady option accumulation signals confidence in Evogene’s AI‑driven biotech growth, hinting at future milestones and potential upside.

EVOGENE insider activity: RECANATI LEON retains 83,886 shares while receiving 2020‑2025 stock‑options that vest quarterly, signaling long‑term confidence in AI‑driven biotech growth.

Insider option grants at Evogene reveal long‑term confidence in its AI drug‑discovery platform, hinting at future upside amid current volatility.